Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Immunogenicity profiling of biopharmaceuticals in immune-mediated inflammatory disease
NL-OMON45746Active, not recruiting
- Sponsor
- Amsterdam University Medical Center
- Start
- Jul 2016
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Open-label trial of adalimumab, etanercept, infliximab, rituximab and tocilizumab in rheumatoid arthritis (RA) and autoimmune inflammatory diseases, sponsored by Amsterdam University Medical Center. Started Jul 2016; status: active, not recruiting.
02
Drugs
03
Conditions
rheumatoid arthritis (RA)autoimmune inflammatory diseases
Beyond the preview
Go deeper on NL-OMON45746.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON45746.